A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

NCT02282826 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Multiple Sclerosis

Interventions

DRUG: GZ402668
DRUG: placebo
DRUG: GZ402668
DRUG: placebo
DRUG: acyclovir

Sponsor

Genzyme, a Sanofi Company